VANCOUVER, BC / ACCESS Newswire / November 25, 2025 /Variational AI, a leading innovator in generative artificial ...

The potential of using artificial intelligence in drug discovery and development has sparked both excitement and skepticism among scientists, investors and the general public. “Artificial intelligence ...

Smart multi-target drugs are redefining how we treat complex diseases by combining AI-driven discovery with mechanistic ...

The rapid advancement of artificial intelligence (AI) is transforming the field of structural biology. In May 2024, DeepMind and Isomorphic Labs launched AlphaFold 3 (AF3), a revolutionary AI system ...

Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday. Thrive Capital, a venture capital firm, led the ...

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding within Google parent company Alphabet, raising $600 million to advance its ...

In drug discovery, scientists identify promising compounds and work to develop them into effective therapeutics. However, they often struggle to navigate expansive compound libraries and prioritize ...

This figure illustrates three key applications of AI in antimicrobial drug development: (1) target identification and validation, including novel target discovery, affinity prediction, multi-target ...

Computational drug discovery and design integrates advanced computer‐aided methodologies with chemical and biological insights to accelerate the identification and optimisation of therapeutic agents.

The integration of artificial intelligence (AI) and machine learning (ML) in oncology clinical trials is rapidly evolving alongside the broader field. For example, AI-driven adaptive trial designs may ...